Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Cost Reimbursement
Drugs
Locations
Clinical Specialty
981-991 of 991 trials

Gastric Cancer: Intraperitoneal Irinotecan Study

We are exploring a new treatment combining intraperitoneal irinotecan with standard therapy for patients with gastric cancer that has spread to the abdomen. This study aims to evaluate its safety, effectiveness, and impact on quality of life.

Gastric Peritoneal Metastases>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementOncology

Metastatic Non-Small Cell Lung Cancer: BMS-986504 Treatment Study

We are studying a new drug, BMS-986504, combined with pembrolizumab and chemotherapy for patients with metastatic non-small cell lung cancer and a specific genetic deletion. The goal is to see if this combination improves survival compared to a placebo treatment.

Metastatic Non-Small Cell Lung CancerEfficacy phase (II)Confirmation phase (III)Investigational MedicinesCost ReimbursementOncology

Migraine Study: Effects of Cilostazol

We are investigating how cilostazol affects migraine headaches in men and women without aura. The study looks at potential differences in response based on sex.

Migraine6-12 monthsSafety phase (I)Efficacy phase (II)≤5 visitsStandard MedicinesCost ReimbursementPartially RemoteNeurology

Vormatrigine for Adults with Epilepsy

We are studying the safety and tolerability of vormatrigine in adults with focal or generalized tonic-clonic seizures. We also aim to explore its effects on seizure frequency and overall patient experience.

Focal Epilepsy and Tonic-Clonic EpilepsyConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Hereditary Angioedema: Navenibart Treatment Study

We are studying whether navenibart can help prevent attacks in adults and adolescents with hereditary angioedema. The trial will also look at its safety and how it affects quality of life.

Hereditary Angioedema1-2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyInternal Medicine

Zoldonrasib for RAS G12D-Mutant Non-Small Cell Lung Cancer

We are studying the effects of zoldonrasib in patients with RAS G12D-mutant non-small cell lung cancer who have been previously treated. The goal is to see how well it works and how safe it is compared to existing treatments.

Non-small Cell Lung Cancer>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncologyPulmonology

Lung Cancer: Zipalertinib with Chemotherapy

We are studying whether adding zipalertinib to chemotherapy helps lung cancer patients with uncommon EGFR mutations after surgery. This trial compares the new treatment to a placebo combined with standard chemotherapy.

Non-small Cell Lung Cancer (NSCLC)Confirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementOncology

Bile Acid Diarrhea: Atorvastatin Treatment Study

We are investigating whether atorvastatin can help reduce bile acid production and improve symptoms in patients with moderate to severe bile acid diarrhea. The study will also look at various health markers and safety.

Bile Acid Diarrhoea3-6 monthsConfirmation phase (III)Monitoring phase (IV)6-10 visitsStandard MedicinesCost ReimbursementGastroenterology

Kidney Protection: Semaglutide and Finerenone in CKD

We are studying how semaglutide and finerenone may help protect the kidneys in people with chronic kidney disease. This includes patients with and without diabetes to explore their effects and mechanisms.

Chronic Kidney Disease6-12 monthsMonitoring phase (IV)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteEndocrinologyNephrology

Influenza Vaccine Study for Adults

We are assessing a new mRNA-based vaccine to see how well it boosts the immune response and its safety in adults aged 18 and older. This study aims to improve protection against seasonal influenza.

Human Influenza6-12 monthsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementInfectious Diseases

CTNNB1 Syndrome: Gene Therapy Study for Kids

We are testing a new gene therapy given through an injection in the brain for children with CTNNB1 syndrome. The study aims to see if it is safe and if it may help improve their condition.

CTNNB1 Syndrome1-2 yearsSafety phase (I)Efficacy phase (II)>20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics